奥翔药业(603229.SH)合作产品枸橼酸托法替布片获得境外上市许可

Core Viewpoint - Aoxiang Pharmaceutical (603229.SH) announced that its partner STADA Arzneimittel AG's subsidiary, Spirig HealthCare AG, has received approval from the Swiss Medicines Agency for the marketing authorization of tofacitinib citrate tablets, marking a significant milestone in the treatment of autoimmune diseases [1] Group 1 - Tofacitinib citrate tablets are the world's first approved oral Janus kinase (JAK) inhibitor, classified as a targeted synthetic disease-modifying antirheumatic drug (DMARD) [1] - The drug works by inhibiting the intracellular JAK signaling pathway, which regulates immune responses [1] - It is primarily used for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, among other autoimmune diseases [1]